Management of epilepsy during pregnancy

Drugs

Volumn 67, Issue 18, 2007, Pages 2727-2746

  Battino, Dina ^a   Tomson, Torbjörn ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiepileptic drugs, adverse reactions; Antiepileptic drugs, therapeutic use; Epilepsy, treatment; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BIRTH DEFECT; BREAST FEEDING; CLEFT LIP; CLEFT PALATE; COGNITION; COGNITIVE DEFECT; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE COURSE; DOSE RESPONSE; DRUG RESPONSE; EPILEPSY; HUMAN; HYPOSPADIAS; METHODOLOGY; MONOTHERAPY; NEURAL TUBE DEFECT; ORAL CLEFT; POSTNATAL DEVELOPMENT; PREGNANCY; PROGENY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TERATOGENESIS; TERATOGENICITY; VITAMIN SUPPLEMENTATION;

EID: 36849060271     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767180-00007     Document Type: Review

References (276)

1. Gaily E. Development and growth in children of epileptic mothers: a prospective controlled study. Acta Obstet Gynecol Scand 1991; 70 (7-8): 631-2
2. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344 (15): 1132-8
3. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004 Jun; 6 (2): 57-75
4. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000 Sep; 41 (2): 107-39
5. Adab N, Tudur SC, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy (Cochrane Review). The Cochrane Library. Chichester (UK); John Wiley and Sons, 2004
6. Lipka K, Bulow HH. Lactic acidosis following convulsions. Acta Anaesthesiol Scand 2003 May; 47 (5): 616-8
7. Hiilesmaa VK, Bardy A, Teramo K. Obstetric outcome in women with epilepsy. Am J Obstet Gynecol 1985; 152 (5): 499-504
8. Teramo K, Hiilesmaa V, Bardy A, et al. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7 (1): 3-6
9. Teramo K, Hiilesmaa V. Pregnancy and fetal complications in epileptic pregnancies. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 53-9
10. The EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006 Feb 14; 66 (3): 354-60
11. Katz O, Levy A, Wiznitzer A, et al. Pregnancy and perinatal outcome in epileptic women: a population-based study. J Matern Fetal Neonatal Med 2006 Jan; 19 (1): 21-5
12. Richmond JR, Krishnamoorthy P, Andermann E, et al. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004; 190 (2): 371-9
13. Schmidt D. The effect of pregnancy on the natural history of epilepsy. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 3-14
14. Bardy AH. Incidence of seizures during pregnancy, labor and puerperium in epileptic women: a prospective study. Acta Neurol Scand 1987; 75 (5): 356-60
15. Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 1985; 39 (1): 33-41
16. Tomson T, Lindbom U, Ekqvist B, et al. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994 Jan-Feb; 35 (1): 122-30
17. Remillard G, Dansky L, Andermann E, et al. Seizure frequency during pregnancy and puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 15-25
18. Canger R, Avanzini G, Battino D, et al. Modifications of seizure frequency in pregnant patients with epilepsy: a prospective study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 33-8
19. Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983; 46 (8): 751-5
20. Nogales Gaete J. The frequency of crises in epileptic women during pregnancy: a prospective study. Rev Med Chil 1986; 114 (11): 1052-7
21. Bag S, Behari M, Ahuja GK, et al. Pregnancy and epilepsy. J Neurol 1989; 236 (5): 311-3
22. Kaneko S. A rational antiepileptic drug therapy of epileptic women in child bearing age. Jpn J Psychiatry Neurol 1988; 42 (3): 473-82
23. Battino D, Binelli S, Bossi L, et al. Monitoring of antiepileptic drugs and hormones in pregnant epileptic women. In: Porter RJ, Mattson RH, Ward AA, et al., editors. Advances in epileptology: the XVth Epilepsy International Symposium. New York: Raven Press, 1984: 227-32
24. Specchio LM, La Neve A, Ostillio G, et al. Frequenza delle crisi epilettiche durante la gravidanza in un'osservazione prospettica. Boll Lega It Epil 1989; 66/67: 299-301
25. Wilhelm J, Morris D, Hotham N. Epilepsy and pregnancy: a review of 98 pregnancies. Aust N Z J Obstet Gynaecol 1990; 30 (4): 290-5
26. Lander CM, Eadie MJ. Plasma antiepileptic drug concentrations during pregnancy. Epilepsia 1991; 32 (2): 257-66
27. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42 (4 Suppl. 5): 75-82
28. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology 1992; 42 (4 Suppl. 5): 89-93
29. Kilpatrick CJ, Hopper JL. The effect of pregnancy on the epilepsies: a study of 37 pregnancies. Aust N Z J Med 1993; 23 (4): 370-3
30. Vidovic MI, Della Marina BM. Trimestral changes of seizure frequency in pregnant epileptic women. Acta Med Croatica 1994; 48 (2): 85-7
31. Sabers A, Rogvi-Hansen B, Dam M, et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol Scand 1998; 97 (3): 164-70
32. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33 (2-3): 145-58
33. Thomas SV, Devi GC, Radhakrishnan K, et al. Seizure pattern during pregnancy and puerperium among women with epilepsy [abstract]. Epilepsia 2001; 41 Suppl. 7: 98
34. Gjerde IO, Strandjord RE, Bakke OM, et al. Epilepsy and pregnancy: seizure incidence and serum concentration of antiepileptic agents. Tidsskr Nor Laegeforen 1985; 105 (31): 2207-9
35. Lander CM, Edwards VE, Eadie MJ, et al. Plasma anticonvulsant concentrations during pregnancy. Neurology 1977; 27 (2): 128-31
36. Krishnamurthy K, Sundstrom D, Beaudoin J, et al. Pregnant women with epilepsy taking older anticonvulsants must have their drug levels checked frequently to avoid seizures [abstract]. Epilepsia 2002; 43 Suppl. 7: 232-3
37. Gjerde IO, Strandjord RE, Ulstein M. The course of epilepsy during pregnancy: a study of 78 cases. Acta Neurol Scand 1988; 78 (3): 198-205
38. Remilliard G, Dansky L, Andermann E, et al. Seizure frequency during pregnancy and the puerperium. In: Janz D, Dam M, Bossi L, et al. editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 15-26
39. Schmidt D. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 39-49
40. Nau H, Kuhnz W, Egger HJ, et al. Anticonvulsants during pregnancy and lactation: transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982; 7 (6): 508-43
41. Kuhnz W, Koch S, Jakob S, et al. Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. Br J Clin Pharmacol 1984; 18 (5): 671-7
42. Pienimaki P, Hartikainen AL, Arvela P, et al. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 1995; 36 (3): 241-8
43. Bulau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34 (3): 311-3
44. Challier JC, Rey E, Bintein T, et al. Passage of S(+) and R(-) gamma-vinyl-GABA across the human isolated perfused placenta. Br J Clin Pharmacol 1992; 34 (2): 139-43
45. Pienimaki P, Lampela E, Hakkola J, et al. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997; 38 (3): 309-16
46. Kimura S. Zonisamide: its placental transport, biological half-life in the newborn, and transport to mother's milk. A study of a case of an infant born of a mother who had been treated with zonisamide alone during pregnancy. No To Hattatsu 1998 Jul; 30 (4): 350-1
47. Tran A, O'Mahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998; 45 (4): 409-11
48. Myllynen P, Pienimaki P, Jouppila P, et al. Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia 2001; 42 (11): 1482-5
49. Kawada K, Itoh S, Kusaka T, et al. Pharmacokinetics of zonisamide in perinatal period. Brain Dev 2002 Mar; 24 (2): 95-7
50. Öhman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002 Oct; 43 (10): 1157-60
51. Myllynen PK, Pienimaki PK, Vahakangas KH. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur J Clin Pharmacol 2003 Feb; 58 (10): 677-82
52. Öhman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005 Oct; 46 (10): 1621-4
53. Mirkin BL. Placental transfer and neonatal elimination of diphenylhydantoin. Am J Obstet Gynecol 1971; 109 (6): 930-3
54. Ploman L, Persson BH. On the transfer of barbiturates to the human foetus and their accumulation in some of its vital organs. J Obstet Gynaecol Br Emp 1957; 64 (5): 706-11
55. Nau H, Rating D, Hauser I, et al. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. Eur J Clin Pharmacol 1980 Jul; 18 (1): 31-42
56. Pynnönen S, Kanto J, Sillanpää M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol 1977; 41 (3): 244-53
57. Perucca E. Drug metabolism in pregnancy, infancy and childhood. Pharmacol Ther 1987; 34 (1): 129-43
58. Krauer B, Krauer F. Drug kinetics in pregnancy. Clin Pharmacokinet 1977; 2 (3): 167-81
59. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and puerperium. Clin Pharmacokinet 2007; 46 (3): 209-19
60. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992 Apr; 42 (4 Suppl. 5): 12-6
61. Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990 Apr; 5 (3): 223-8
62. Battino D, Avanzini G, Bossi L, et al. Monitoring of antiepileptic drugs plasma levels during pregnancy and puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 147-54
63. Bardy AH, Hiilesmaa VK, Teramo KA. Serum phenytoin during pregnancy, labor and puerperium. Acta Neurol Scand 1987; 75 (6): 374-5
64. Tomson T, Lindbom U, Ekqvist B, et al. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994 Jan-Feb; 35 (1): 131-5
65. Dansky L, Andermann E, Shervin A, et al. Plasma levels of phenytoin during pregnancy ant the puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 155-62
66. Battino D, Binelli S, Bossi L, et al. Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery. Clin Pharmacokinet 1985 May-Jun; 10 (3): 279-84
67. Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit 1985; 7 (3): 269-73
68. Lander CM, Livingstone I, Tyrer JH, et al. The clearance of anticonvulsant drugs in pregnancy. Clin Exp Neurol 1981; 17: 71-8
69. Battino D, Binelli S, Bossi L, et al. Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium. Clin Pharmacokinet 1984 May-Jun; 9 (3): 252-60
70. Rating D, Nau H, Jager-Roman E, et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatr Scand 1982 Mar; 71 (2): 301-11
71. Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol Scand 1985 Nov; 72 (5): 460-3
72. Öhman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000 Jun; 41 (6): 709-13
73. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002 Jul 23; 59 (2): 251-5
74. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004 Jan; 62 (2): 292-5
75. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004 Aug; 63 (3): 571-3
76. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005 Jul; 65 (3): 185-8
77. Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006 Oct 10; 67 (7): 1297-9
78. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006 Mar; 47 (3): 504-9
79. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006 Oct 24; 67 (8): 1497-9
80. Gramstrom ML. Development of the children of epileptic mothers: preliminary results from the prospective Helsinki study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 403-8
81. Pennell PB, Koganti A, Helmers S, et al. The impact of pregnancy and childbirth on the elimination of levetiracetam [abstract]. Epilepsia 2005 Oct; 46 Suppl. 8: 89
82. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007 Mar 22; 48 (6): 1111-6
83. Vajda FJ, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006 Jun; 13 (6): 645-54
84. Sabers A, Dam MA, Rogvi-Hansen B, et al. Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9-13
85. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004 Oct; 45 (10): 1171-5
86. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects (prospective study). Lancet 1976; I (7954): 272-5
87. Majewski F, Steger M, Richter B, et al. The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Int J Biol Res Pregnancy 1981; 2 (1): 37-45
88. Friis ML, Hauge M. Congenital heart defects in live-born children of epileptic parents. Arch Neurol 1985; 42 (4): 374-6
89. Meyer JG. The teratological effects of anticonvulsants and the effects on pregnancy and birth. Eur Neurol 1973; 10 (3): 179-90
90. Beck-Mannagetta G, Drees G, Janz D. Malformations and minor anomalies in the offspring of epileptic parents: a retrospective study. In: Janz D, Dam M, Bossi L, et al. editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 317-23
91. Koch S, Hartmann A, Jager E. Major malformation in children of epileptic mothers: due to epilepsy or its therapy? In: Janz D, Dam M, Richens A, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 313-6
92. Rating D, Jager-Roman E, Koch S, et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. Pharmacokinetics in teratogenesis. Boca Raton (FL): CRC Press, 1987: 205-24
93. Koch S, Losche G, Jager-Roman E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992; 42 (4 Suppl. 5): 83-8
94. Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004; 27 (3): 197-202
95. Akhtar N, Millac P. Epilepsy and pregnancy: a study of 188 pregnancies in 92 patients. Br J Clin Pract 1987; 41 (8): 862-4
96. Al Bunyan M, Abo-Talib Z. Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure 1999; 8 (1): 26-9
97. Anderman E, Duncan S, Mercho S, et al. Safety of carbamazepine exposure during pregnancy [abstract]. Epilepsia 2003; 44 Suppl. 8: 35
98. Barry JE, Danks DM. Anticonvulsants and congenital abnormalities [letter]. Lancet 1974; II (7871): 48-9
99. Bertollini R, Kallen B, Mastroiacovo P, et al. Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 1987; 3 (2): 164-71
100. Buchanan N. Epilepsy and pregnancy: a review of 26 patients. N Z Med J 1988; 101 (851): 509-10
101. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40 (9): 1231-6
102. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005 Mar 22; 64 (6): 955-60
103. Dansky L, Anderman E, Anderman F. Major congenital malformation in the offspring of epileptic patients: genetic and environmental risk factors. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 223-34
104. Duncan S, Mercho S, Lopes-Cendas I, et al. The effects of valproic acid on the outcome of pregnancy: a prospective study [abstract]. Epilepsia 2003; 44 Suppl. 8: 59
105. Elshove J, van Eck JH. Congenital abnormalities, cleft lip and cleft palate in particular, in children of epileptic mothers. Ned Tijdschr Geneeskd 1971 Aug 14; 115 (33): 1371-5
106. Eskazan E, Aslan S. Antiepileptic therapy and teratogenicity in Turkey. Int J Clin Pharmacol Ther Toxicol 1992; 30 (8): 261-4
107. Fabris C, Licata D, Stasiowska B, et al. Newborn infants from epileptic mothers: malformation and auxonologic risk. Pediatr Med Chir 1989; 11 (1): 27-31
108. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000; 321 (7262): 674-5
109. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. BMJ 1973; 2 (5864): 442-8
110. Goujard J, Huel G, Rumeau-Rouquette C. Anti-epileptics and congenital malformations. J Gynecol Obstet Biol Reprod (Paris) 1974; 3 (6): 831-42
111. Higgins TA, Comerford JB. Epilepsy in pregnancy. J Ir Med Assoc 1974; 67 (11): 317-20
112. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61 (5): 673-8
113. Holmes LB, Wyszynski DF, Baldwin EJ, et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract]. Birth Defects Research (Part A): Clinical and Molecular Teratology 2006; 78: 318
114. Hunt SJ, Morrow JI. Safety of antiepileptic drugs during pregnancy. Expert Opin Drug Saf 2005 Sep; 4 (5): 869-77
115. Hvas CL, Henriksen TB, Ostergaard JR. Birth weight in offspring of women with epilepsy. Epidemiol Rev 2000; 22 (2): 275-82
116. Janz D, Fuchs U. Are anti-epileptic drugs harmful during pregnancy? Dtsch Med Wochenschr 1964 Feb 7; 89: 241-8
117. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997; 17 (3): 561-4
118. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003 Feb 25; 60 (4): 575-9
119. Kallen B. Maternal epilepsy, antiepileptic drugs and birth defects. Pathologica 1986; 78 (1058): 757-68
120. Katz JM, Pacia SV, Devinsky O. Current management of epilepsy and pregnancy: fetal outcome, congenital malformations, and developmental delay. Epilepsy Behav 2001 Apr; 2 (2): 119-23
121. Knight AH, Rhind EG. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 1975; 16 (1): 99-110
122. Kondo T, Kaneko S, Amano Y, et al. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37 (12): 1242-4
123. Kuenssberg EV, Knox JD. Teratogenic effect of anticonvulsants. Lancet 1973; I (7796): 198
124. Lander CM, Eadie MJ. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990; 7 (1): 77-82
125. Laskowska M, Leszczynska-Gorzelak B, Oleszczuk J. Pregnancy in women with epilepsy. Gynecol Obstet Invest 2001; 51 (2): 99-102
126. Lekwuwa GU, Adewole IF, Thompson MO. Antiepileptic drugs and teratogenicity in Nigerians. Trans R Soc Trop Med Hyg 1995; 89 (2): 227
127. Lindhout D, Meinardi H, Barth P. Hazards of fetal exposure to drugs combination. In: Janz D, Dam M, Bossi L, et al. editors. Epilepsy, pregnancy, and the child. New York: Raven Press 1982: 275-82.
128. Lindhout D, Meinardi H, Meijer JW, et al. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42 (4 Suppl. 5): 94-110
129. Loiseau P, Henry TP. Teratogenic hazards in antiepileptic therapy [letter]. Nouv Presse Med 1974; 3 (2): 92
130. Lowe CR. Congenital malformations among infants born to epileptic women. Lancet 1973; I (7793): 9-10
131. Maroni E, Markoff R. Epilepsy and pregnancy. Gynaecologia 1969; 168 (6): 418-21
132. Martin F. Pregnancy and epilepsy. Rev Med Suisse Romande 1978; 98 (4): 199-208
133. Martin PJ, Millac PA. Pregnancy, epilepsy, management and outcome: a 10-year perspective. Seizure 1993; 2 (4): 277-80
134. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004; 5 (2): 163-7
135. Melchior JC, Svensmark O, Trolle D. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 1967 Oct 21; II (7521): 860-1
136. Montouris G, Creasy G, Khan A, et al. Pregnancy outcome in topiramate-treated pregnancy [abstract]. Epilepsia 2003; 44 Suppl. 9: 290
137. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003; 4 (3): 310-7
138. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006 Feb; 77 (2): 193-8
139. Niswander JD, Wertelecki W. Congenital malformation among offspring of epileptic women [letter]. Lancet 1973; I (7811): 1062
140. Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68 (1): 18-24
141. Oguni M, Dansky L, Andermann E, et al. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992; 14 (6): 371-80
142. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998; 39 (8): 887-92
143. Omtzigt JG, Los FJ, Hagenaars AM, et al. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn 1992; 12 (11): 893-7
144. Pandian JD, Abraham M, Chacko B, et al. Pregnancy and epilepsy: results of Ludhiana Center of Indian Registry for Epilepsy and Pregnancy [abstract]. 25th International Epilepsy Congress; 2003 Oct 12-16; Lisbon
145. Sabin M. Epilepsy and pregnancy. Obstet Gynecol 1956; 7 (2): 175-9
146. Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997 Sep; 38 (9): 981-90
147. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46 (5): 739-46
148. Sawhney H, Vasishta K, Suri V, et al. Pregnancy with epilepsy: a retrospective analysis. Int J Gynaecol Obstet 1996; 54 (1): 17-22
149. Sonneveld SW, Correy JF. Outcome of pregnancies complicated by epilepsy in Tasmania 1981-1988. Aust N Z J Obstet Gynaecol 1990; 30 (4): 286-9
150. South J. Teratogenic effect of anticonvulsants. Lancet 1972; II (7787): 1154
151. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of fetus and the newborn. Lancet 1972; II (7782): 839-43
152. Starreveld-Zimmerman AA, van der Kolk WJ, Meinardi H, et al. Are anticonvulsants teratogenic? Lancet 1973; II (819): 48-9
153. Svigos JM. Epilepsy and pregnancy. Aust N Z J Obstet Gynaecol 1984; 24 (3): 182-5
154. Viinikainen K, Heinonen S, Eriksson K, et al. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006; 47 (1): 186-92
155. Watson JD, Spellacy WN. Neonatal effects of maternal treatment with the anticonvulsant drug diphenylhydantoin. Obstet Gynecol 1971; 37 (6): 881-5
156. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64 (6): 961-5
157. Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptics and the development of congenital anomalies. Neurology 1992; 42 (4 Suppl. 5): 132-40
158. Annegers JF, Hauser I. The frequency of malformations in relative of patients with epilepsy. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 267-3
159. Deblay MF, Vert P, Andre M. Children of epileptic mothers [in French]. Nouv Presse Med 1982; 11 (3): 173-6
160. Gaily E, Granstrom ML, Hiilesmaa V, et al. Minor anomalies in offspring of epileptic mothers. J Pediatr 1988; 112 (4): 520-9
161. Holmes LB, Rosenberger PB, Harvey EA, et al. Intelligence and physical features of children of women with epilepsy. Teratology 2000; 61 (3): 196-202
162. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320 (25): 1661-6
163. Kelly TE, Edwards P, Rein M, et al. Teratogenicity of anticonvulsant drugs: II, a prospective study. Am J Med Genet 1984; 19 (3): 435-43
164. Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002 Dec; 11 (8): 512-8
165. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006 Aug 8; 67 (3): 407-12
166. Steegers-Theunissen RP, Renier WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Res 1994; 18 (3): 261-9
167. Thomas D, Buchanan N. Teratogenic effects of anticonvulsants [letter]. J Pediatr 1981; 99 (1): 163
168. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005 Jun 14; 64 (11): 1874-8
169. Biale Y, Lewenthal H, Aderet NB. Congenital malformations due to anticonvulsive drugs. Obstet Gynecol 1975; 45 (4): 439-42
170. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984; 18 (4): 211-6
171. Bjerkedal T. Outcome of pregnancy in women with epilepsy, Norway, 1967 to 1978: congenital malformations. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 289-96
172. Burja S, Rakovec-Felser Z, Treiber M, et al. The frequency of neonatal morbidity after exposure to antiepileptic drugs in utero: a retrospective population-based study. Wien Klin Wochenschr 2006; 118 Suppl. 2: 12-6
173. Giraud JR, Hoppeler JM, Mettey R, et al. The teratogenic risks of anti-epileptic treatment. J Gynecol Obstet Biol Reprod 1982; 11 (3): 385-91
174. Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992; 42 (4 Suppl. 5): 68-74
175. Laine-Cessac P, Le Jaoen S, Rosenau L, et al. Uncontrolled retrospective study of 75 pregnancies in women treated for epilepsy. J Gynecol Obstet Biol Reprod (Paris) 1995; 24 (5): 537-42
176. Markestad T, Ulstein M, Strandjord RE, et al. Anticonvulsant drug therapy in human pregnancy: effects on serum concentrations of vitamin D metabolites in maternal and cord blood. Am J Obstet Gynecol 1984; 150 (3): 254-8
177. Millar JH, Nevin NC. Congenital malformations and anticonvulsant drugs [letter]. Lancet 1973; I (7798): 328
178. Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8 (1): 75-8
179. Seino M, Miyakoshi M. Teratogenic risks of antiepileptic drugs in respect to the type of epilepsy. Folia Psychiatr Neurol Jpn 1979; 33 (3): 379-85
180. Stanley FJ, Priscott PK, Johnston R, et al. Congenital malformations in infants of mothers with diabetes and epilepsy in Western Australia, 1980-1982. Med J Aust 1985; 143 (10): 440-2
181. Waters CH, Belai Y, Gott PS, et al. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994; 51 (3): 250-3
182. Weber M, Schweitzer M, Andre JM, et al. Epilepsy, anticonvulsants and pregnancy. Arch Fr Pediatr 1977; 34 (4): 374-83
183. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93 (2): 174-6
184. Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39 (4): 251-9
185. Diav-Citrin O, Shechtman S, Arnon J, et al. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001; 57 (2): 321-4
186. D'Souza SW, Robertson IG, Donnai D, et al. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Arch Dis Child 1991; 66 (3): 320-4
187. Fonager K, Larsen H, Pedersen L, et al. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000; 101 (5): 289-94
188. Hill BC, Verniaud WM, Rettig GM, et al. Relation between antiepileptic drug exposure of the infant and developmental potential. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 409-17
189. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29 (4): 459-67
190. Nakane Y. The teratological problem of antiepileptic drugs. Folia Psychiatr Neurol Jpn 1980; 34 (3): 277-87
191. van der Pol MC, Hadders-Algra M, Huisjes HJ, et al. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am J Obstet Gynecol 1991; 164 (1 Pt 1): 121-8
192. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004 Nov; 45 (11): 1463-4
193. Tomson T, Battino D, French J, et al. Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries. ETDP Workgroup on Teratogenicity-Anatomical. Epilepsy Behav 2007; 11 (3): 277-82
194. Nakane Y. Factors influencing the risk of malformations among infants born to epileptic mothers. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 259-66
195. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996 Dec; 75 (6): 517-20
196. Annegers JF, Elveback LR, Hauser WA, et al. Do anticonvulsants have a teratogenic effect? Arch Neurol 1974; 31 (6): 364-73
197. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the
198. Dansky L. Outcome of pregnancy in epileptic women [PhD thesis]. Montreal, QC: McGill University, 1989
199. Meadow SR. Congenital abnormalities and anticonvulsant drugs. Proc R Soc Med 1970; 63 (1): 48-9
200. Van Dyke DC, Hodge SE, Heide F, et al. Family studies in fetal phenytoin exposure. J Pediatr 1988 Aug; 113 (2): 301-6
201. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001; 42 (6): 750-3
202. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42 (4 Suppl. 5): 111-8
203. Waziri M, Ionasescu V, Zellweger H. Teratogenic effect of anticonvulsant drugs. Am J Dis Child 1976; 130 (9): 1022-3
204. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001; 98 (2): 168-75
205. Ozkinay F, Yenigun A, Kantar M, et al. Two siblings with fetal hydantoin syndrome. Turk J Pediatr 1998; 40 (2): 273-8
206. Karpathios T, Zervoudakis A, Venieris F, et al. Genetics and fetal hydantoin syndrome. Acta Paediatr Scand 1989; 78 (1): 125-6
207. Gardner RJ, Savarirayan R, Dunne KB, et al. Microlissencephaly with cardiac, spinal and urogenital defects. Clin Dysmorphol 2001; 10 (3): 203-8
208. Erickson JD. Facial and oral form in sibs of children with cleft lip with or without cleft palate. Ann Hum Genet 1974; 38 (1): 77-88
209. Malm H, Kajantie E, Kivirikko S, et al. Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology 2002 Aug 27; 59 (4): 630-3
210. Pashayan H, Pruzansky D, Qruzansky S. Are anticonvulsants teratogenic? Lancet 1971; II (7726): 702-3
211. Dronamraju KR. Epilepsy and cleft lip and palate. Lancet 1970 Oct 24; II (7678): 876-7
212. Abrishamchian AR, Khoury MJ, Calle EE. The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case-control study. Genet Epidemiol 1994; 11 (4): 343-51
213. Kelly TE, Rein M, Edwards P. Teratogenicity of anticonvulsant drugs: IV, the association of clefting and epilepsy. Am J Med Genet 1984; 19 (3): 451-8
214. Friis ML. Epilepsy among parents of children with facial clefts. Epilepsia 1979; 20 (1): 69-76
215. Erickson JD, Oakley GP. Seizure disorder in mothers of children with orofacial clefts: a case-control study. J Pediatr 1974; 84 (2): 244-6
216. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; II (8304): 937
217. Lindhout D, Meinardi H. Spina bifida and in-utero exposure to valproate. Lancet 1984; II (8399): 396
218. Greenberg G, Inman WH, Weatherall JA, et al. Maternal drug histories and congenital abnormalities. BMJ 1977 Oct 1; 2 (6091): 853-6
219. Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108 (6): 997-1004
220. Vajda FJ, O'Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003 Sep; 10 (5): 543-9
221. Bertollini R, Mastroiacovo P, Segni G. Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). Eur J Epidemiol 1985; 1 (1): 67-72
222. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000; 41 (11): 1436-43
223. Hernandez-Diaz S, Werler MM, Walker AM, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153 (10): 961-8
224. Kallen B, Robert E, Mastroiacovo P, et al. Anticonvulsant drugs and malformations: is there a drug specificity? Eur J Epidemiol 1989; 5 (1): 31-6
225. Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42 (4 Suppl. 5): 119-25
226. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; I (8494): 1392-3
227. Annegers JF, Hauser WA, Elveback LR, et al. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978; 7 (3): 241-7
228. Rodriguez-Pinilla E, Arroyo I, Fondevilla J, et al. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000; 90 (5): 376-81
229. Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005 May; 21 (5): 693-701
230. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006 Nov 28; 67 (10): 1876-9
231. Wide K, Winbladh B, Tomson T, et al. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev Med Child Neurol 2000 Feb; 42 (2): 87-92
232. Steinhausen HC, Losche G, Koch S, et al. The psychological development of children of epileptic parents: I. Study design and comparative findings. Acta Paediatr 1994; 83 (9): 955-60
233. Gaily E, Kantola-Sorsa E, Granström ML. Intelligence of children of epileptic mothers. J Pediatr 1988; 113 (4): 677-84
234. Losche G, Steinhausen HC, Koch S, et al. The psychological development of children of epileptic parents: II, the differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994; 83 (9): 961-6
235. Fujioka K, Kaneko S, Hirano T, et al. A study of the psychomotor development of the offspring of epileptic mothers. In: Sato T, Shinagawa S, editors. Antiepileptic drugs and pregnancy. Amsterdam-Princeton-Geneva-Tokyo: Excerpta Medica, 1984: 196-206
236. Jager-Roman E, Fating D, Koch S. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 425-32
237. Koch S, Gopfert-Geyer I, Jager-Roman E, et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development. Dtsch Med Wochenschr 1983; 108 (7): 250-7
238. Nomura Y, Takabe Y, Nomura Y. The physical and mental development of infants born to mothers treated with antiepileptic drugs. In: Sato T, Shinagawa S, editors. Antiepileptic drugs and pregnancy. Amsterdam: Excerpta Medica, 1984: 187-95
239. Beck-Mannagetta G, Janz D. Data on psychomotor and mental development in children of epileptic mothers: a retrospective study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 443-5
240. Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89 (4): 662-8
241. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994 Mar 9; 271 (10): 767-70
242. Hattig H, Helge H, Steinhausen H. Infants of epileptic mothers: development scores at 18 months. In: Wolf P, Dam M, Janz D, editors. Advances in epileptology. New York: Raven Press, 1987: 403-8
243. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004 Nov; 75 (11): 1575-83
244. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 1982; 32 (11): 1247-54
245. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70 (1): 15-21
246. Leavitt AM, Yerby MS, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992; 42 (4 Suppl. 5): 141-3
247. Wide K, Henning E, Tomson T, et al. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002; 91 (4): 409-14
248. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32 (5): 403-14
249. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62 (1): 28-32
250. Rovet J, Cole S, Nulman I, et al. Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychol 1995; 1 (2): 150-7
251. Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005 Mar 22; 64 (6): 949-54
252. Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40 (9): 1237-43
253. Vanoverloop D, Schnell RR, Harvey EA, et al. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992; 14 (5): 329-35
254. Dessens AB, Boer K, Koppe JG, et al. Studies on long-lasting consequences of prenatal exposure to anticonvulsant drugs. Acta Paediatr Suppl. 1994; 404: 54-64
255. Ohtsuka Y, Silver K, Lopes-Cendes I, et al. Effect of antiepileptic drugs on psychomotor development of offspring of epileptic mothers [abstract]. Epilepsia 1999; 40 Suppl. 2: 296
256. Eriksson K, Viinikainen K, Monkkonen A, et al. Children exposed to valproate in utero: population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005 Jul 16; 65 (3): 189-200
257. Viinikainen K, Eriksson K, Monkkonen A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav 2006 Dec; 9 (4): 636-40
258. Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. Implications for prevention. JAMA 1995 Dec 6; 274 (21): 1698-702
259. Kirke PN, Molloy AM, Daly LE, et al. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993 Nov; 86 (11): 703-8
260. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995 Jan 21; 345 (8943): 149-51
261. Yates JR, Ferguson-Smith MA, Shenkin A, et al. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet 1987 May; 31 (5): 279-87
262. Botto LD, Moore CA, Khoury MJ, et al. Neural-tube defects. N Engl J Med 1999 Nov 11; 341 (20): 1509-19
263. Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol 1992; 8 (1): 122-7
264. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343 (22): 1608-14
265. Hiilesmaa VK, Teramo K, Granstrom ML, et al. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. BMJ (Clin Res Ed) 1983; 287 (6392): 577-9
266. Dansky LV, Andermann E, Rosenblatt D, et al. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987; 21 (2): 176-82
267. Dansky L, Wolfson C, Anderman E, et al. A multivariate analysis of risk factors for major congenital malformations in offspring of epileptic women [abstract]. Epilepsia 1989; 30: 678
268. Moore JL. The significance of folic acid for epilepsy patients. Epilepsy Behav 2005 Sep; 7 (2): 172-81
269. Stokes T, Juarez-Garcia A, Camosso-Stefinovic J, et al. Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners, 2004
270. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005; 46 Suppl. 9: 117-24
271. von Unruh GE, Froescher W, Hoffmann F, et al. Valproic acid in breast milk: how much is really there? Ther Drug Monit 1984; 6 (3): 272-6
272. Froescher W, Eichelbaum M, Niesen M, et al. Carbamazepine levels in breast milk. Ther Drug Monit 1984; 6 (3): 266-71
273. Kuhnz W, Koch S, Helge H, et al. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 1988; 11 (3): 147-54
274. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005 May; 46 (5): 775-7
275. Shimoyama R, Ohkubo T, Sugawara K. Monitoring of zonisamide in human breast milk and maternal plasma by solid-phase extraction HPLC method. Biomed Chromatogr 1999; 13 (5): 370-2
276. Tomson T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther Drug Monit 2005 Dec; 27 (6): 718-21